Hoth Therapeutics Starts Preclinical Study For Its Alzheimer's Candidate

by Vandana Singh, Benzinga Editor

August 2, 2021 11:11 AM | 1 min read | Make a Comment

Hoth Therapeutics Inc HOTH has initiated its preclinical study utilizing Hoth's HT-ALZ in an animal model.
The study aims to determine the effects of HT-ALZ on behavioral and pathological markers of Alzheimer's disease and determine if HT-ALZ can improve learning and memory in an animal model of Alzheimer's disease.
Hoth study will also determine if the behavior is improved utilizing HT-ALZ in blocking NK-1Rs.
The designed studies are taking place under a Scientific Research Agreement entered by Hoth in June 2021.
Price Action: HOTH shares are up 3.87% at $1.34 during the market session on the last check Monday.

Posted In: Biotech News Penny Stocks Health Care General Alzheimer's disease Briefs

Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.